CPB has made an encouraging start to fiscal 2015, with better-than-expected first-quarter results.

After Campbell Soup (CPB) experienced a nasty tumble following its November earnings report, I concluded the stock was too expensive to warrant the risk. As it turned out, CPB made a perfect bottom after its post-earnings collapse and went on to print two buyable rallies.

Everything you need to know about the markets and what you may have missed over night in one free daily newsletter.

June E-mini S&Ps (ESM14 -0.19%) this morning are down -0.36% and European stocks are down -0.75%. AstraZeneca is down 13% in pre-market trading and is leading health-care stocks lower after it rejected Pfizer's upward revised $117 billion bid for the company as too low.

The average large cap score is 59.35, above the four week moving average score of 58.46. The average large cap stock is trading -10% below its 52 week high, 3.11% above its 200 dma, has 3.87 days to cover held short, and is expected to grow EPS by 13.5% next year.